Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 29:277-282, 2006
DOI: 10.2337/diacare.29.02.06.dc05-1913
© 2006 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow patientINFORMation
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Becker, R. H.A.
Right arrow Articles by Fountaine, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Becker, R. H.A.
Right arrow Articles by Fountaine, R. J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Emerging Treatments and Technologies
Original Article

The Effect of Smoking Cessation and Subsequent Resumption on Absorption of Inhaled Insulin

Reinhard H.A. Becker, MD, PHD1, Sue Sha, MD, PHD2, Annke D. Frick, PHD1 and Robert J. Fountaine, PHARMD2

1 Aventis Pharma Deutschland, Frankfurt, Germany
2 Pfizer Global Research and Development, Groton, Connecticut

Address correspondence and reprint requests to Reinhard H.A. Becker, Clinical Discovery and Human Pharmacology, Aventis Pharma Deutschland, Industriepark Höchst, Building H831, Room C0441, 65926 Frankfurt am Main, Germany. E-mail: reinhard.becker{at}sanofi-aventis.com

OBJECTIVE—To assess the absorption profile of inhaled insulin in healthy, actively smoking subjects at baseline, after smoking cessation, and after smoking resumption and compare it with nonsmoking subjects.

RESEARCH DESIGN AND METHODS—Insulin pharmacokinetics and glucodynamics were measured in 20 male smoking subjects (10–20 cigarettes/day) and 10 matched nonsmoking subjects after receiving inhaled insulin (1 mg) or the approximate subcutaneous insulin equivalent (3 units) in a randomized cross-over fashion. All smokers then received inhaled insulin 12 h, 3 days, and 7 days into a smoking cessation period. They then resumed smoking for 2–3 days before again receiving inhaled insulin 1 h after the last cigarette.

RESULTS—Before smoking cessation, maximum insulin concentration (Cmax) and area under the curve (AUC) for insulin concentration time (AUC-Insulin0–360) with inhaled insulin were higher, and time to Cmax (tmax) shorter, in smokers than nonsmokers (Cmax 26.8 vs. 9.7 µU/ml; AUC-Insulin0–360 2,583 vs. 1,645 µU · ml–1 · min–1; tmax 20 vs. 53 min, respectively; all P < 0.05), whereas with subcutaneous insulin, systemic exposure was unchanged (AUC-Insulin0–360 2,324 vs. 2,269 µU · ml–1 · min–1; P = NS). After smoking cessation, AUC-Insulin0–360 decreased with inhaled insulin by up to 50% within 1 week and approached nonsmoker levels. Cmax decreased and tmax increased relative to baseline but were still not comparable with nonsmoker values. Smoking resumption completely reversed the effect of smoking cessation. Glucodynamics corroborated the observed findings in insulin pharmacokinetics.

CONCLUSIONS—Cessation and resumption of smoking greatly altered the pharmacokinetics of inhaled insulin. As rapid changes in systemic insulin exposure increase hypoglycemia risk, inhaled insulin should not be used in people with diabetes who choose to continue smoking. This is consistent with recommendations that people with diabetes refrain from smoking altogether.

Abbreviations: AUC, area under the curve


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Find additional patient-related information at:

Smoking Reverses Benefits of Inhaled Insulin


This article has been cited by other articles:


Home page
 Diabetes CareHome page
A. H. Petersen, G. Kohler, S. Korsatko, A. Wutte, M. Wonisch, O. K. Jeppesen, T. Sparre, P. Clauson, T. Laursen, P. Wollmer, et al.
The Effect of Exercise on the Absorption of Inhaled Human Insulin via the AERx Insulin Diabetes Management System in People With Type 1 Diabetes
Diabetes Care, October 1, 2007; 30(10): 2571 - 2576.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
L. A. Kroon
Drug interactions with smoking
Am. J. Health Syst. Pharm., September 15, 2007; 64(18): 1917 - 1921.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
K. Rave, A. de la Pena, F. S. Tibaldi, L. Zhang, B. Silverman, M. Hausmann, L. Heinemann, and D. B. Muchmore
AIR Inhaled Insulin in Subjects With Chronic Obstructive Pulmonary Disease: Pharmacokinetics, glucodynamics, safety, and tolerability
Diabetes Care, July 1, 2007; 30(7): 1777 - 1782.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. T. McMahon and R. A. Arky
Inhaled Insulin for Diabetes Mellitus
N. Engl. J. Med., February 1, 2007; 356(5): 497 - 502.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
W. T. Cefalu
Point: Pulmonary Inhalation of Insulin: Another "Brick in the Wall"
Diabetes Care, February 1, 2007; 30(2): 439 - 441.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
L. Ceglia, J. Lau, and A. G. Pittas
Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus.
Ann Intern Med, November 7, 2006; 145(9): 665 - 675.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2006 by the American Diabetes Association.